Opioid-induced Constipation
33
1
1
20
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
15 trials with published results (45%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
21.2%
7 terminated out of 33 trials
74.1%
-12.4% vs benchmark
55%
18 trials in Phase 3/4
75%
15 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (33)
Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications
European Study of Opioid Induced Constipation
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
Colonic Motor Patterns in Healthy Volunteers
A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
Study of Opioid-Induced Constipation 2 Project
Study of Opioid-Induced Constipation 1 Project
Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
Compassionate Use Study of Methylnaltrexone
Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation
Long Term Safety of Naldemedine